HUMAN LONGEVITY, INC.
SAN DIEGO, CA

Human Longevity, Inc. (HLI), was founded by leaders in genomics with the ultimate goal of giving everyone access to the power of data-driven health intelligence. HLI combines state-of-the-art DNA sequencing and expert analysis with machine learning, to help change medicine to a more data-driven science. With a multidisciplinary team of research scientists, computing experts and physicians, we are empowering every part of the healthcare system to work more efficiently. Products and Services Human Longevity, Inc. (HLI), was founded by leaders in genomics with the ultimate goal of giving everyone access to the power of data-driven health intelligence. HLI combines state-of-the-art DNA sequencing and expert analysis with machine learning, to help change medicine to a more data-driven science. With a multidisciplinary team of research scientists, computing experts and physicians, we are empowering every part of the healthcare system to work more efficiently. Products and Services Saturnino (Nino) Fanlo serves as Chief Financial Officer and Chief Operating Officer at Human Longevity. Prior to joining HLI, Fanlo was most recently with Social Finance, Inc. (Sofi), the largest and fastest growing online lender, where he served as President and Chief Financial Officer. Fanlo was a key leader at Sofi who worked hand in hand with the CEO and founder to design and build capital markets, loan sale, finance, and credit and loan operations there. He led five successful capital raises for more than $1.9 billion and moved the company from an $8 million to a $4.3 billion valuation in under five years. He was also a key architect of many of Sofi’s unique financial products. Prior to Sofi Fanlo held a series of high level leadership roles in well-respected financial services firms. Before Sofi, he was a Senior Advisor at Golden Gate Capital where he helped to develop their $1 billion Credit Opportunity Fund and the $200 million Public Equity Fund. For 5 years, he served as the CEO of KKR Financial (NYSE:KFN), and CIO and Partner of KKR Asset Management where was responsible for capital raising, investment policy, portfolio selection and management, recruiting and development, and investor communications. He led the initial public offering of KKR Financial after just nine months of establishing this spinout. He also raised $ 4 billion in equity capital and $10 billion of permanent investment capital. Products and Services Heather Kowalski is Chief Administrative Officer at Human Longevity, Inc. In this role she oversees marketing, public relations, human resources, facilities, and security. Prior to this role she was head of public relations and marketing. Before joining HLI, Heather was Chief of Staff and VP of Communications for the J. Craig Venter Institute. She began to hone her genomics communications experience at Celera Genomics where she was Director of Communications during the company’s historic sequencing of the human genome. Products and Services William Biggs, PhD is Head of Genomic Sequencing for HLI. He and his team are building the largest genomic sequencing facility in the world which currently has two Illumina HiSeq XTen sequencing systems, growing to a total of 40 sequencers. He comes to the company from the Clinical Research Sequencing Platform (CRSP) at the Broad Institute of MIT and Harvard where he was the Director of Clinical Sequencing. In his role at CRSP he and his team supported pivotal clinical diagnostic, research and trials efforts to identify applications for deep sequencing in the process of medical decision-making. He was also responsible for assisting in the assembly of an evidence base required for broad-based reimbursement and utilization of deep sequencing in patient management. Prior to joining the Broad Institute Dr. Biggs was the Director of Genetics and Genomics at Aviir Diagnostic Laboratories. Prior joining Aviir, Dr. Biggs as Director of Technical Operations, was a member of the founding team at Affymetrix Clinical Service Laboratories. Dr. Biggs obtained his Ph.D. in Biological Chemistry from UCLA in 1994 and has extensive experience in elucidating the roles of genetics, signal transduction and transcriptional regulation during the initiation of progression of disease gained during studies conducted at The Salk Institute, The Ludwig Institute for Cancer Research, and Ambit Biosciences. Products and Services Sally Howard, JD, serves as Head of Regulatory Affairs and Policy for HLI. Howard, who has more than two decades of health policy and regulatory expertise, leads all efforts related to federal and state regulatory oversight for HLI. Howard comes to HLI from the United States Food and Drug Administration (FDA) where she served most recently as Senior Advisor and Acting Chief of Staff to the FDA Commissioner. In this role, Howard coordinated the FDA’s response to rapidly emerging issues such as bacteria resistant infections from medical equipment and response to adverse events from compounded drugs. She also spent two years as FDA Deputy Commissioner for Policy, Planning and Legislation, during which time she directed the team implementing the White House’s Precision Medicine Initiative. She and her team were responsible for developing a standards based approach for ensuring accuracy of genomic tests, and the use of genomic data and databases for clinical and diagnostic use. She was also a key leader on FDA legislative initiatives such as the 21st Century Cures initiative which seeks to modernize the approach to patient centered drug development, and the development of biomarkers. Prior to her role at the FDA, Howard spent two years as Chief of Staff at the U.S. Department of Health and Human Services (HHS), where she worked directly with the Secretary and senior agency and administration leadership to develop and implement policy priorities including the Affordable Care Act and new standards for Electronic Health Records. Products and Services Jill Westman Mullen serves as the SVP, Investor Relations for Human Longevity Inc. Ms. Mullen began her career as a management consultant with Andersen Consulting (now Accenture) specializing operational and technology enhancements to the financial services industry. From there, she progressed to serve as Managing Director for GE Capital Services in Stamford, CT, followed by First Vice President and Chief Technology Officer for Merrill Lynch & Co. in New York. There she was responsible for global technology support to the corporate functions, including finance, treasury and human resources. Most recently, she served as Vice President for Perot Systems of Dallas TX, where she was Head of the Financial Services Industry Group and managed the New York office. Over the course of her career, Ms. Mullen has led an information technology services business, directed numerous complex technology initiatives and managed a multitude of clients, staff, and technology platforms across the financial services marketplace in the U.S., Europe, the Middle East, and Asia.